These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 26372098)

  • 21. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
    Suzuki R; Wei X; Allen PK; Cox JD; Komaki R; Lin SH
    Clin Lung Cancer; 2019 Mar; 20(2):117-123. PubMed ID: 30611672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
    Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
    Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer.
    Wang J; Kalhor N; Hu J; Wang B; Chu H; Zhang B; Guan Y; Wu Y
    PLoS One; 2016; 11(10):e0163397. PubMed ID: 27695079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection.
    Takahashi Y; Horio H; Hato T; Harada M; Matsutani N; Morita S; Kawamura M
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1324-31. PubMed ID: 26198075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
    Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
    Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 34. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
    Park HS; Harder EM; Mancini BR; Decker RH
    J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Eriguchi T; Takeda A; Sanuki N; Tsurugai Y; Aoki Y; Oku Y; Hara Y; Akiba T; Shigematsu N
    Lung Cancer; 2017 Jul; 109():62-67. PubMed ID: 28577952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.
    Lian L; Xia YY; Zhou C; Shen XM; Li XL; Han SG; Zheng Y; Mao ZQ; Gong FR; Wu MY; Chen K; Tao M; Li W
    Cancer Biomark; 2015; 15(6):899-907. PubMed ID: 26444485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematologic Markers of Lung Metastasis in Stage IV Colorectal Cancer.
    Abu-Shawer M; Abu-Shawer O; Souleiman M; Akkawi M; Alshakhatreh O; Altamimi T; Al-Omari A; Al-Hussaini M
    J Gastrointest Cancer; 2019 Sep; 50(3):428-433. PubMed ID: 29589285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
    Rice SJ; Belani CP
    PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.